Asymmetrical high-flow nasal cannula performs similarly to standard interface in patients with acute hypoxemic post-extubation respiratory failure: a pilot study.

"Declarations Ethics approval and consent to participateThe study was approved by the Institutional Ethics Committee of Padua University Hospital (reference number: AOP2949) and written informed consent was obtained from all patients. Consent for publicationNot applicable. Competing interestsPN research lab received grants/research equipment by Draeger, Mindray, Intersurgical SPA and Gilead. PN receives royalties from Intersurgical SPA for Helmet Next invention. He also received speaking fees from Getinge, Intersurgical SPA, Gilead, MSD, Draeger. NS and FZ received speaking fees from Getinge. The other authors have no other competing interests to declare. Competing interests PN research lab received grants/research equipment by Draeger, Mindray, Intersurgical SPA and Gilead. PN receives royalties from Intersurgical SPA for Helmet Next invention. He also received speaking fees from Getinge, Intersurgical SPA, Gilead, MSD, Draeger. NS and FZ received speaking fees from Getinge. The other authors have no other competing interests to declare."

"Funding No funding was received for the present study. The asymmetrical HFNC interfaces were kindly provided by Fisher & Paykel Healthcare (New Zealand) only for research purposes, without any economic interests. The industry was not involved in any phase of the study."

"Clinical trial number ClinicalTrial.gov. Registration number: NCT05838326 (01/05/2023)."